A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans.

导出 OA

翻译打印收藏纠错

作者： Francisco J,Caballero-Camino ^[1] ; Pedro M,Rodrigues ^[2] ; Fredrik,Wångsell ^[1] ; Aloña,Agirre-Lizaso ^[3] ; Paula,Olaizola ^[4] ; Laura,Izquierdo-Sanchez ^[5] ; Maria J,Perugorria ^[1] ; Luis,Bujanda ^[1] ; Bo,Angelin ^[3] ; Sara,Straniero ^[1] ; Anna,Wallebäck ^[3] ; Ingemar,Starke ^[1] ; Per-Göran,Gillberg ^[2] ; Ellen,Strängberg ^[3] ; Britta,Bonn ^[1] ; Jan P,Mattsson ^[2] ; Martin R,Madsen ^[3] ; Henrik H,Hansen ^[6] ; Erik,Lindström ^[6] ; Peter,Åkerblad ^[5] ; Jesus M,Banales ^[5]

作者单位： Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain. ^[1] Department of Medicine, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain. ^[2] National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), Madrid, Spain. ^[3] Ikerbasque, Basque Foundation for Science, Bilbao, Spain. ^[4] Albireo AB, Göteborg, Sweden. ^[5] CardioMetabolic Unit, Department of Medicine and Clinical Department of Endocrinology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden. ^[6] Gubra, Hoersholm, Denmark. ^[7] Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain. ^[8]